Loading
A phase 1 trial of BTM-3566 run by Bantam Pharmaceuticals, now recruiting.
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas is a phase 1 interventional study registered as NCT06792734 by Bantam Pharmaceuticals, with 24 participants planned, started 2025-02-14. Conditions recorded: Lymphoma, B-Cell. Interventions recorded: BTM-3566.
Shares Bantam Pharmaceutical, BTM-3566 and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/